Get started
Author

Shuming Lin

Observed institution: Innovent Biologics (China)
ORCID: 0009-0005-8715-9026
Observed ORCID: 0009-0005-8715-9026
OpenAlex ID: A5101328894
B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities
2026 · Jian Guan, Tiongsun Chia, et al. · Nature Communications · 3
PDF
Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors
2024 · Jian Guan, Shuaixiang Zhou, et al. · Cancer Research · 2
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
2026 · Jia Liu, Jingbo Ma, et al. · Cancer Research
Abstract LB053: A novel CD16A-nanobody platform overcomes Fc polymorphism limitations for potent and broad-spectrum NK cell engager therapeutics
2026 · Tiong Sun Chia, Jia Liu, et al. · Cancer Research
Abstract 4249: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies
2025 · Tiongsun Chia, Weiwei Wu, et al. · Cancer Research
Works count: 5
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type